Latest Medicago Stories

QUEBEC CITY, QC and SAINT PAUL, MN, Jan. 16, 2012 /PRNewswire/ - Medicago Inc. (MDG: TSX), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a subsidiary of Cellectis SA (Alternext: ALCLS), the French specialist in genome engineering, today announced the signing of a research agreement under which Medicago and Cellectis will collaborate to...

QUEBEC CITY, Dec. 16, 2011 /PRNewswire/ - Medicago Inc. ("Medicago" or the "Corporation") (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), announces that further to the press release dated December 15, 2011, the second tranche of the investment of $22.5 million by Philip Morris Investments B.V. ("PM Investments") has now closed. This second...

QUEBEC CITY, Dec. 15, 2011 /PRNewswire/ - Medicago Inc. ("Medicago" or the "Corporation") (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), announces that its shareholders have approved the second tranche of the previously announced investment of $22.5 million by Philip Morris Investments B.V. ("PM Investments"). At the special meeting of the...

FIVE POINTS, Calif., Nov. 22, 2011 /PRNewswire/ -- S&W Seed Company (Nasdaq: SANW) today announced that it has leased 1,500 acres of Madera County farmland. The 1,500 Madera acres are in addition to 800 acres of leased farmland in Kern County, announced by the company in April 2011. The Madera and Kern locations will both be used primarily for growing S&W's proprietary alfalfa seed for harvesting in calendar 2012. Since its founding in 1982, S&W has relied almost exclusively on...

The genome of Medicago, a close relative of alfalfa and a long-established model for the study of legume biology, has been sequenced by an international team of scientists, capturing around 94 per cent of its genes. The research gives new insights into the evolution of the Papilionoid subfamily of legumes, which includes peas, soybean and all legumes grown as crops. Plants in this family can house and work with bacteria to provide them with nitrogen from the air. The new findings...

Genome gives clues into legume evolution, and could provide means to better understand and better utilize closely related agricultural crops such as alfalfa ROCKVILLE, Md., Nov. 16, 2011 /PRNewswire-USNewswire/ -- Scientists from the J. Craig Venter Institute (JCVI), along with a team of international researchers led by those at the University of Minnesota, have sequenced and published a draft genome of the model legume, Medicago truncatula, also known by its common name, "barrel medic."...

QUEBEC CITY, Nov. 14, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the third quarter ended September 30, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "This was another quarter of progress...

RALEIGH, North Carolina and QUEBEC CITY, Quebec, Nov. 10, 2011 /PRNewswire/ - Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with North Carolina Governor Beverly Perdue, U.S. Senator Richard Burr and Congressman David Price, are holding an...

QUEBEC CITY, Nov. 9, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbe, the Company's Chief Financial Officer, has been invited to present at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will be held at The Pierre Hotel in New York City on November...

- Receives Approval to Proceed to Second Stage of Agreement - QUEBEC CITY, Oct. 12, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful completion of the first stage of its research collaboration, announced initially on April 6, 2011, with a top 10 global pharmaceutical company for the...